These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 23557064)

  • 21. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor: A novel treatment option for nurse practitioners treating patients with psoriatic disease.
    Young M; Roebuck HL
    J Am Assoc Nurse Pract; 2016 Dec; 28(12):683-695. PubMed ID: 27869356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apremilast for the treatment of psoriatic arthritis.
    Souto A; Gómez-Reino JJ
    Expert Rev Clin Immunol; 2015; 11(12):1281-90. PubMed ID: 26503917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
    Bissonnette R; Pariser DM; Wasel NR; Goncalves J; Day RM; Chen R; Sebastian M
    J Am Acad Dermatol; 2016 Jul; 75(1):99-105. PubMed ID: 27021239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apremilast in benign chronic pemphigus (Hailey-Hailey disease).
    Riquelme-Mc Loughlin C; Iranzo P; Mascaró JM
    Clin Exp Dermatol; 2020 Aug; 45(6):737-739. PubMed ID: 32198945
    [No Abstract]   [Full Text] [Related]  

  • 25. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
    Volf EM; Au SC; Dumont N; Scheinman P; Gottlieb AB
    J Drugs Dermatol; 2012 Mar; 11(3):341-6. PubMed ID: 22395585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic tearing induced by apremilast.
    Norris MR; Bielory L
    Ann Allergy Asthma Immunol; 2018 Sep; 121(3):375. PubMed ID: 29969663
    [No Abstract]   [Full Text] [Related]  

  • 27. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    Yiu ZZ; Warren RB
    Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Maier C; Ramming A; Bergmann C; Weinkam R; Kittan N; Schett G; Distler JHW; Beyer C
    Ann Rheum Dis; 2017 Jun; 76(6):1133-1141. PubMed ID: 28209630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
    Harrison C
    Nat Rev Drug Discov; 2013 May; 12(5):335. PubMed ID: 23629496
    [No Abstract]   [Full Text] [Related]  

  • 30. Emerging Oral Immunomodulators for the Treatment of Psoriasis: A Review of Phase III Clinical Trials for Apremilast and Tofacitinib.
    McAndrew R; Levin E; Koo J
    J Drugs Dermatol; 2015 Aug; 14(8):786-92. PubMed ID: 26267722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Appearance of lentigines in psoriasis patients treated with apremilast.
    Sfecci A; Khemis A; Lacour JP; Montaudié H; Passeron T
    J Am Acad Dermatol; 2016 Dec; 75(6):1251-1252. PubMed ID: 27846946
    [No Abstract]   [Full Text] [Related]  

  • 32. Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.
    Kavanaugh A; Mease PJ; Gomez-Reino JJ; Adebajo AO; Wollenhaupt J; Gladman DD; Hochfeld M; Teng LL; Schett G; Lespessailles E; Hall S
    J Rheumatol; 2015 Mar; 42(3):479-88. PubMed ID: 25593233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.
    De Souza A; Strober BE; Merola JF; Oliver S; Franks AG
    J Drugs Dermatol; 2012 Oct; 11(10):1224-6. PubMed ID: 23134988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.
    Krase IZ; Cavanaugh K; Curiel-Lewandrowski C
    JAMA Dermatol; 2016 Mar; 152(3):348-50. PubMed ID: 26536384
    [No Abstract]   [Full Text] [Related]  

  • 35. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
    Page CP; Spina D
    Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study.
    Paller AS; Hong Y; Becker EM; de Lucas R; Paris M; Zhang W; Zhang Z; Barcellona C; Maes P; Fiorillo L
    J Am Acad Dermatol; 2020 Feb; 82(2):389-397. PubMed ID: 31408686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of Phosphodiesterase-4 in Psoriatic Arthritis and Inflammatory Bowel Diseases.
    Picchianti-Diamanti A; Spinelli FR; Rosado MM; Conti F; Laganà B
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of ethanol abstinence-induced anxiety- and depressive-like behavior by the phosphodiesterase-4 inhibitor rolipram in rodents.
    Gong MF; Wen RT; Xu Y; Pan JC; Fei N; Zhou YM; Xu JP; Liang JH; Zhang HT
    Psychopharmacology (Berl); 2017 Oct; 234(20):3143-3151. PubMed ID: 28748375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
    Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
    J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue.
    Spadaccini M; D'Alessio S; Peyrin-Biroulet L; Danese S
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28617319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.